The rationale of this RCT was that IL-1—despite the fact that it is notoriously difficult to measure in the circulation—may play a pathophysiological role in CFS, and its activity may be confined to the brain compartment [23]. This evidence concerns the gene IL1B and myalgic encephalomeyelitis/chronic fatigue syndrome.